Amgen: Japan Supreme Court Rejects Sanofi Appeal on PCSK9 Patent

Supreme Court of Japan on April 24 upheld decision that Sanofi’s Praluent infringes Amgen’s patents covering a narrow class of antibodies that inhibit the PCSK9 human protein, Amgen says in statement.

Court ruling means Sanofi is prohibited from manufacturing, distributing, importing, or offering to distribute Praluent in Japan
Amgen KK, the marketing authorization holder of PCSK9 inhibitor Repatha, will implement injunction

To view the source of this information click here

To contact the reporter on this story:
Michael Sin in Hong Kong at msin12@bloomberg.net

To contact the editor responsible for this story:
Ryan Lovdahl at rlovdahl@bloomberg.net

To read the full article log in.

Learn more about a Bloomberg Law subscription